Facebook
Twitter
LinkedIn
Forward
Understanding Meibomian Gland Dysfunction as a Driver for Dry Eye Disease (Online CME Monograph)
Activity Description and Purpose
Meibomian gland dysfunction (MGD) is a common condition affecting the ocular surface. Changes in the functioning of the meibomian glands result in alteration of oily secretions, or meibum, from the glands that form the outer lipid layer of tear film. Meibum is responsible for helping to lubricate the ocular surface, facilitating the spread of tears, and reducing evaporation. The presence of MGD is a major contributing factor to the development of dry eye disease. Understanding the signs and symptoms of MGD can help ophthalmologists achieve a differential diagnosis and connect the impact of this chronic condition to the development and progression of dry eye disease. The desired results of this educational activity are for ophthalmologists to understand the epidemiology and underlying pathophysiology of MGD, diagnostic techniques, and current and emerging treatments.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the prevalence of meibomian gland dysfunction
- Describe the pathophysiology of meibomian gland dysfunction–associated dry eye disease
- Implement best practices for diagnosing patients with meibomian gland dysfunction
Faculty
 | John Sheppard, MD, MMSc, FACS (Chair) Professor of Ophthalmology Eastern Virginia Medical School President Virginia Eye Consultants Medical Director Lions Eye Bank of Eastern Virginia Norfolk, Virginia |
 | Marjan Farid, MD Professor of Ophthalmology Director of Cornea, Cataract, and Refractive Surgery Vice Chair of Ophthalmic Faculty Gavin Herbert Eye Institute University of California, Irvine Irvine, California |
 | Christopher E. Starr, MD, FACS
|
 | David Wirta, MD
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Marjan Farid, MD, is a consultant for Allergan, Bausch & Lomb Incorporated, Bio-Tissue, CorneaGen, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss; and is an advisory board member of Allergan, Bausch & Lomb Incorporated, Bio-Tissue, CorneaGen, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss.
John Sheppard, MD, MMSc, is a consultant for AbbVie Inc, Aldeyra Therapeutics, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, Clearside Biomedical, Inc, Dompé US, Inc, Eleven Biotherapeutics, Hovione, Johnson & Johnson Vision Care, Inc, KOWA Pharmaceuticals America, Inc, NovaBay Pharmaceuticals, Inc, Noveome Biotherapeutics, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Quidel Corporation, ScienceBased Health, Sun Pharmaceutical Industries, Inc, TearLab Corporation, TearScience, TissueTech, Inc, and Vistakon; is an advisory board member of Alcon, Aldeyra Therapeutics, Allergan, ArcScan, Inc, Avedro, Inc, Bausch & Lomb Incorporated, BioLayer, Bruder Healthcare, Clearside Biomedical, Inc, ClearView Healthcare Partners, Clementia Pharmaceuticals Inc, Dompé US, Inc, Eyedetec Medical, Eyevance, Glaukos Corporation, Hovione, Imprimis Pharmaceuticals, Inc, Inspire Pharmaceuticals, Inc, Ionis Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Kiora Pharmaceuticals, Inc, KOWA Pharmaceuticals America, Inc, LacriSciences LLP, LayerBio, Inc, Lenstatin, Lux Biosciences, Mallinckrodt, Mati Therapeutics, Inc, Merck & Co., Inc, Mitotech, SA, Nicox, NovaBay Pharmaceuticals, Inc, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Noveome Biotherapeutics, Inc, OcuCure Therapeutics, Inc, Oculis, Okogen, Inc, Omeros Corporation, Oyster Point Pharma, Inc, Parion Sciences, Portage Biotech, Inc, Quidel Corporation, Rapid Pathogen Screening, Inc, Santen Inc, Shire, Sun Pharmaceutical Industries, Inc, Synedgen, Takeda Pharmaceuticals USA, Inc, Talia Technology, TearLab Corporation, TearScience, TopiVert Ltd, and Vistakon; is on the speakers bureau for AbbVie Inc, Alcon, Allergan, Avedro, Inc, Bausch & Lomb Incorporated, Bio-Tissue, Dompé US, Inc, Eleven Biotherapeutics, Inspire Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, Kiora Pharmaceuticals, Inc, Lumenis Be Ltd, Mallinckrodt, Merck & Co., Inc, Nicox, Novartis Pharmaceuticals Corporation, Omeros Corporation, Pfizer Inc, Santen Inc, ScienceBased Health, Takeda Pharmaceuticals USA, Inc, Talia Technology, TearLab Corporation, TearScience, TissueTech, Inc, Topcon Medical Systems, Inc, and Vistakon; is a contracted researcher for AbbVie Inc, Alcon, Aldeyra Therapeutics, Allergan, ArcScan, Inc, Avedro, Inc, Bausch & Lomb Incorporated, Clearside Biomedical, Inc, ClearView Healthcare Partners, Clementia Pharmaceuticals, Dompé US, Inc, EyeRx Research, Inc, Glaukos Corporation, Hovione, InSite Vision, Inc, Inspire Pharmaceuticals, Inc, Ionis Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Kiora Pharmaceuticals, Inc, LacriSciences LLP, Lux Biosciences, Merck & Co., Inc, NeoMedix Corporation, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Okogen, Inc, Parion Sciences, Pfizer Inc, Rapid Pathogen Screening, Inc, R-Tech Ueno, Ltd, Santen Inc, Senju Pharmaceutical Co, Ltd, Servier, Shire, TearScience, TearSolutions, Topcon Medical Systems, Inc, Vistakon, and XOMA; and has individual stocks or stock options in ALPHAEON Corporation, BioLayer, EyeRx Research, Inc, Eyevance, Kiora Pharmaceuticals, Inc, LacriSciences LLP, LayerBio, Inc, Mati Therapeutics, Inc, NovaBay Pharmaceuticals, Inc, Noveome Biotherapeutics, Inc, OccuHub, OcuCure Therapeutics, Okogen, Inc, Rapid Pathogen Screening, Inc, Shire, and TearLab Corporation.
Christopher E. Starr, MD, is a consultant for Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Allergan, Bruder Healthcare, Dompé US, Inc, EyeBio, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Quidel Corporation, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, and Verséa; and has individual stocks or stock options in Èssiri Labs.
David Wirta, MD, is a consultant for Aerie Pharmaceuticals, Inc, Eyenovia, Inc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Santen Inc; and is a contracted researcher for AbbVie, Aerie Pharmaceuticals, Inc, Allergan, Allysta Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Eyenovia, Inc, Jenivision Inc, Nicox, Novaliq GmbH, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Ora, Inc, Orasis Pharmaceuticals, Osmotica Pharmaceuticals plc, Oyster Point Pharma, Inc, Qlaris Bio, Inc, Santen Inc, Sight Sciences, Tersus Pharmaceuticals, and Visus Therapeutics.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Kurt Brubaker is a consultant for Aquinas, Lexitas Pharma Services, and 2e/Fire and Rain.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Bausch & Lomb Incorporated, EyeNet, or the American Academy of Ophthalmology.
©2023 MedEdicus LLC. 275
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation